These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18555919)

  • 1. Clinical trials of orphan medicines.
    Buckley BM
    Lancet; 2008 Jun; 371(9629):2051-5. PubMed ID: 18555919
    [No Abstract]   [Full Text] [Related]  

  • 2. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME
    N Engl J Med; 2006 Feb; 354(5):445-7. PubMed ID: 16452556
    [No Abstract]   [Full Text] [Related]  

  • 5. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 6. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 7. Orphan drug development in China: progress and challenges.
    Zhang S; Chen L; Zhang Z; Zhao Y
    Lancet; 2019 Sep; 394(10204):1127-1128. PubMed ID: 31571591
    [No Abstract]   [Full Text] [Related]  

  • 8. Statistical considerations for rare diseases drug development.
    Chow SC; Chang YW
    J Biopharm Stat; 2019; 29(5):874-886. PubMed ID: 31454299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new toolkit for conducting clinical trials in rare disorders: will this dog hunt?
    Peterson RG; Macleod SM; Klein AV
    J Popul Ther Clin Pharmacol; 2014; 21(1):e79-80. PubMed ID: 24671905
    [No Abstract]   [Full Text] [Related]  

  • 11. Financing drug discovery for orphan diseases.
    Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
    Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovative design and analysis for rare disease drug development.
    Chow SC; Huang Z
    J Biopharm Stat; 2020 May; 30(3):537-549. PubMed ID: 32065047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The pharmacist, rare diseases and orphan medicines].
    Nagore Induráin C; Lacalle E; Arteche L
    An Sist Sanit Navar; 2008; 31 Suppl 2():127-43. PubMed ID: 18953376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The routes to orphan drug designation--our recent experience at the FDA.
    Lev D; Thorat C; Phillips I; Thomas M; Imoisili MA
    Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120
    [No Abstract]   [Full Text] [Related]  

  • 16. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S
    Mol Interv; 2006 Aug; 6(4):186-91. PubMed ID: 16960139
    [No Abstract]   [Full Text] [Related]  

  • 19. A father's fight to help his sons - and fix clinical trials.
    Adam D
    Nature; 2019 Jan; 565(7738):148-151. PubMed ID: 30626961
    [No Abstract]   [Full Text] [Related]  

  • 20. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.